10.69
0.23 (2.20%)
| Previous Close | 10.46 |
| Open | 10.61 |
| Volume | 1,488,222 |
| Avg. Volume (3M) | 2,149,032 |
| Market Cap | 1,734,281,344 |
| Price / Earnings (Forward) | 27.17 |
| Price / Sales | 5.40 |
| Price / Book | 2.04 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Profit Margin | -0.67% |
| Operating Margin (TTM) | 7.19% |
| Diluted EPS (TTM) | -0.020 |
| Quarterly Revenue Growth (YOY) | 9.70% |
| Total Debt/Equity (MRQ) | 28.51% |
| Current Ratio (MRQ) | 2.78 |
| Operating Cash Flow (TTM) | 93.52 M |
| Levered Free Cash Flow (TTM) | 71.36 M |
| Return on Assets (TTM) | 1.12% |
| Return on Equity (TTM) | -0.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bullish | Mixed |
| Health Information Services (Global) | Bullish | Mixed | |
| Stock | Certara, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.5 |
| Average | 0.25 |
|
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 2.48% |
| % Held by Institutions | 100.90% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 16.00 (Barclays, 49.67%) | Buy |
| 16.00 (Keybanc, 49.67%) | Buy | |
| 16.00 (Craig-Hallum, 49.67%) | Buy | |
| Median | 16.00 (49.67%) | |
| Low | 15.00 (UBS, 40.32%) | Buy |
| Average | 15.75 (47.33%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 12.51 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Keybanc | 08 Oct 2025 | 16.00 (49.67%) | Buy | 13.00 |
| Barclays | 02 Oct 2025 | 16.00 (49.67%) | Buy | 13.60 |
| Craig-Hallum | 29 Sep 2025 | 16.00 (49.67%) | Buy | 12.18 |
| UBS | 07 Aug 2025 | 15.00 (40.32%) | Buy | 11.26 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 Oct 2025 | Announcement | Certara Scientists are Among the Topmost Cited Biopharma Researchers |
| 10 Oct 2025 | Announcement | Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025 |
| 04 Sep 2025 | Announcement | Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster |
| 02 Sep 2025 | Announcement | Certara to Participate in Upcoming Investor Conferences |
| 06 Aug 2025 | Announcement | Certara Reports Second Quarter 2025 Financial Results |
| 04 Aug 2025 | Announcement | Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling |
| 04 Aug 2025 | Announcement | Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling |
| 31 Jul 2025 | Announcement | Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |